Medical Technologies Innovation and Knowledge Centre Phase 2 Regenerative Devices

再生设备(支架、生物材料和干预)可以使用患者自身的细胞修复和再生组织，可以转化为成功的临床产品，为患者带来更低的成本和风险，并且比培养扩增细胞疗法或分子(药物)疗法等其他再生疗法所需的时间更短。据估计，到2020年，全球再生设备市场将增长到500亿GB，这为英国在该领域每年增长10亿GB的行业提供了真正的机会。英国在生物材料和组织工程、肌肉骨骼力学(EPSRC优先考虑)和再生医学领域拥有真正的研究实力。再生医学是研究委员会优先考虑的八大技术之一。研究发现、新知识、产出和成果往往还没有准备好被业界接受，无法通过产品开发推广到市场和患者的利益。新技术需要先进并降低风险。需要确定临床需求、潜在产品和市场，以便使它们对行业的投资、产品开发和临床试验具有吸引力。在医疗技术创新和知识中心(MTIKC)第一阶段，我们与业界和临床合作伙伴合作，培养了一支专业的创新团队和独特的创新和翻译流程，创建了一个多学科的研究和创新生态系统。我们成功地识别了研究成果和新知识，并创造、先进和转化了跨越创新之谷的技术，使行业和私营部门能够成功地投资于新产品开发(超过1亿GB)。一些产品已经进入临床试验和商业化，并正在实现对患者的好处。我们已经建立了50多个概念技术项目的持续创新管道。在未来五年的MTIKC第二阶段，我们将解决伤口修复、心血管修复、肌肉骨骼组织修复、颌面重建、牙齿重建和普通外科方面未得到满足的临床需求和市场机会，并将我们的研究供应链多元化到其他十多所大学。我们将支持150个与行业合作的项目，并启动40个新的行业启发和学术主导的概念验证项目，预计这些项目将导致私营部门在后续产品开发中进一步投资1亿GB。这将使英国能够建立一条可持续的研究和产品开发管道，在2020年后支持每年10亿GB的再生设备行业。

Regenerative devices (scaffolds, biomaterials and interventions) which can repair and regenerate tissues using the patients` own cells, can be translated into successful clinical products and deliver patient benefit at much lower cost and risk and in shorter timescales then other regenerative therapies such as culture expanded cell therapies or molecular (drug) therapies. It is estimated that the global market for regenerative devices will grow to £50bn by 2020 and this offers a real opportunity to grow a £1bn per year industry in the UK in this field. The UK has genuine research strengths in the areas of biomaterials and tissue engineering, musculoskeletal mechanics (prioritised by EPSRC) and regenerative medicine. Regenerative medicine is one of the eight great technologies prioritised across the Research Councils. Research discoveries, new knowledge, outputs and outcomes are often not ready for uptake by industry to take forward through product development to the market and patient benefit. New technologies need to be advanced and de-risked. The clinical needs, potential products and markets need to be defined in order to make them attractive for investment, product development and clinical trials by industry. In the Medical Technologies Innovation and Knowledge Centre (MTIKC) Phase 1, working with industry and clinical partners, we have developed a professional innovation team and a unique innovation and translation process, creating a multidisciplinary research and innovation ecosystem. We have successfully identified research outcomes and new knowledge and created, advanced and translated technology across the innovation valley of death, enabling successful investment (over £100m) by industry and the private sector in new product development. Some products have already progressed to clinical trials and commercialisation and are realising patient benefits. We have established a continuous innovation pipeline of over fifty proofs of concept technology projects.Over the next five years in MTIKC Phase 2, we will address unmet clinical needs and market opportunities in wound repair, cardiovascular repair, musculoskeletal tissue repair, maxillofacial reconstruction, dental reconstruction and general surgery and diversify our research supply chain to over ten other Universities. We will support 150 collaborative projects with industry and initiate forty new industry inspired and academically led proof of concept projects, which are predicted to lead to a further £100m investment by the private sector in subsequent product development. This will enable a sustainable research and product development pipeline to be established in the UK which will support a £1bn / year industry in regenerative devices beyond 2020.